Albertsons Companies Inc vs Illumina, Inc. — how do they compare? Albertsons Companies Inc trades at $12.19 (market cap $5.89B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is far larger — about 4.9× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays a 5.61% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ACI | ILMN | |
|---|---|---|
Market Cap | $5.89B | $28.96B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $205.10 |
52-Week Low | $11.03 | $91.00 |
Enterprise Value | $21.29B | $30.32B |
Dividend Yield | 5.61% | — |
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.01, down 0.58% with bearish technical signals despite recent insider buying by the CEO and CFO. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains strong revenue growth trends. Valuation metrics show a high P/E ratio of 75.06 but attractive P/S of 0.08, while profitability remains challenged with net margins at just 0.08%.
The outlook remains cautious with analyst consensus at Buy (35%) but significant legal investigations and margin pressure creating headwinds. The $13.20 price target offers 10% upside potential, though execution risks and competitive grocery market dynamics require careful monitoring for sustained recovery.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Trailing returns across standard periods
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →